Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "continuous renal replacement therapy"

Trimethoprim and Sulfamethoxazole Transmembrane Clearance duri...

General Please address all your queries or problem reports to the Pay-per-View Customer Service at info@karger.com referring to PPV or PPV account. 1. All payments are by credit card only. The transaction is secure: standard-procedure SSL or ... Sexual Development, 4 days ago

14 images for continuous renal replacement therapy

MDLinx, 1 week ago
MDLinx, 1 week ago
MDLinx, 1 week ago
MDLinx, 1 week ago
MDLinx, 1 week ago
MDLinx, 1 week ago
MDLinx, 1 week ago
MDLinx, 1 week ago
MDLinx, 1 week ago
MDLinx, 1 week ago

Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in critically ill patients: a systematic review

1 Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China 2 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical University, Fuzhou 350001, Fujian, China ...
 Critical Care1 week ago Citrate for continuous renal replacement therapy: safer, better and cheaper  Critical Care2 weeks ago
Securities Technology Monitor

Rockwell Medical Closes $58.5 Million Public Offering of Common Stock

Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary ...
 Individual.com3 weeks ago Rockwell Medical Prices $58.5 Million Public Offering of Common Stock  Individual.com4 weeks ago Rockwell Medical Announces $55 Million Proposed Public Offering of Common Stock  Individual.com1 month ago Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at the American Society of Nephrology (ASN) Meeting November 2014  Individual.com1 month ago
[x]  

CPXX: The DSMB Recommends Phase III to Continue

By Grant Zeng, CFA NASDAQ:CPXX On Dec. 1, 2014, Celator ( CPXX ) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase III clinical study of CPX-351 has completed a second planned safety review and ...
 Yahoo! Finance2 weeks ago

Re: Concerns over use of hydroxyethyl starch solutions

Hartog and colleagues argue (1) against the decision of the European Medicines Agency (EMA) (2) to allow the continued use of hydroxyethyl starch (HES), and advise physicians to avoid HES solutions altogether. They base their advice primarily on ...
 British Medical Journal1 month ago Acrux : European Medicines Agency Testosterone update  4 Traders3 weeks ago News and press releases: No consistent evidence of an increased risk of heart problems with testosterone medicines  European Medicines Agency4 weeks ago No consistent evidence of an increased risk of heart problems with testosterone medicines  FiercePharma4 weeks ago

Ears and Hearing Effects Continue to Reverberate after Boston Marathon Bombing

Acute kidney injury occurs frequently in Ebola virus disease; however, providing hemodialysis to these patients was previously thought to be too risky. Clinicians recently accomplished the first known successful delivery of renal replacement therapy ...
 Infrosoft1 month ago

Ardelyx Appoints Jeremy S. Caldwell, Ph.D., as Executive Vice President and Chief Scientific Officer [Kuwait News Agency]

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced the appointment of Jeremy S. Caldwell, Ph.D., as Executive Vice President and Chief Scientific Officer. Dr.
 Pharmacy Choice2 weeks ago Ardelyx Inc. (ARDX) Appoints Jeremy S. Caldwell, Ph.D., As Executive Vice President And Chief Scientific Officer  FierceBiotech2 weeks ago Ardelyx Inc. Appoints As Executive Vice President And Chief Scientific Officer  BioSpace2 weeks ago Ardelyx : Appoints Jeremy S. Caldwell, Ph.D., as Executive Vice President and Chief Scientific Officer  4 Traders2 weeks ago
[x]  

Data Investigating KEYTRUDA® (pembrolizumab), Merck's Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium

Merck ( NYSE: MRK ), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the company's anti-PD-1 therapy, as assessed by ...
 Street Sweeper1 week ago MERCK : Data Investigating KEYTRUDA┬« (pembrolizumab), Merck's Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium  4 Traders1 week ago Data Investigating KEYTRUDA(r) (pembrolizumab), Merck's Anti-PD-1 T...  Finwin1 week ago Merck Releases Keytruda (pembrolizumab) Data  Individual.com4 days ago
[x]  
TeleTrader.com

International Breast Cancer Study Group , Breast International Group And Merck & Co. Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer

Collaborative Trial is First to Investigate an Anti-PD-1 Therapy, Pembrolizumab, Combined with Trastuzumab Study to Explore Whether New Approach May Reverse Trastuzumab Resistance in Cancer with Significant Unmet Need SAN ANTONIO--(BUSINESS ...
 BioSpace1 week ago MERCK : International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer  4 Traders1 week ago
[x]  

New Data at ASH 2014 Highlight Progress of Pfizer's Growing Portfolio in Blood Cancers

It is gratifying to see continued progress of Pfizer's in-line and pipeline portfolio against a broad array of hematologic malignancies, said Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs ...
 Morningstar.com1 week ago New Data At American Society of Hematology 2014 Highlight Progress Of Pfizer (PFE)'s Growing Portfolio In Blood Cancers 12/9/2014  ClinicSpace1 week ago PFIZER : New Data at ASH 2014 Highlight Progress of Pfizer's Growing Portfolio in Blood Cancers  4 Traders1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less